Actavis Must Withdraw Opana ER Generic Four Years After Launch
This article was originally published in The Pink Sheet Daily
Court finds Actavis infringed two Endo patents, judge to decide whether to award damages. Actavis' non-crush-resistant generic has impeded sales of Endo's newer crush-resistant version.
Register for our free email digests: